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A B S T R A C T   
Previous studies have established the role of Na+/H+ exchanger isoform-1 (NHE1) and cathepsin B (Cat B) in the 
development of cardiomyocyte hypertrophy (CH). Both NHE1 and Cat B are activated under acidic conditions 
suggesting that their activities might be interrelated. The inhibition of NHE1 has been demonstrated to reduce 
cardiac hypertrophy but the mechanism that contributes to the anti-hypertrophic effect of NHE1 inhibition still 
remains unclear. H9c2 cardiomyoblasts were stimulated with Angiotensin (Ang) II in the presence and absence of 
N-[2-methyl-4,5-bis(methylsulphonyl)-benzoyl]-guanidine, hydrochloride (EMD, EMD 87580), an NHE1 inhib-
itor or CA-074Me, a Cat B inhibitor, and various cardiac hypertrophic parameters, namely cell surface area, 
protein content and atrial natriuretic peptide (ANP) mRNA were analyzed. EMD significantly suppressed markers 
of cardiomyocyte hypertrophy and inhibited Ang II stimulated Cat B protein and gene expression. Cat B is located 
within the acidic environment of lysosomes. Cat B proteases are released into the cytoplasm upon disintegration 
of the lysosomes. EMD or CA-074Me prevented the dispersal of the lysosomes induced by Ang II and reduced the 
ratio of LC3-II to LC3-I, a marker of autophagy. Moreover, Cat B protein expression and MMP-9 activity in the 
extracellular space were significantly attenuated in the presence of EMD or CA-074Me. Our study demonstrates a 
novel mechanism for attenuation of the hypertrophic phenotype by NHE1 inhibition that is mediated by a 
regression in Cat B. The inhibition of Cat B via EMD or CA-074Me attenuates the autosomal-lysosomal pathway 
and MMP-9 activation.   
1. Introduction 
Cardiovascular diseases (CVDs) continue to be the major reason for 
death globally, regardless of the progress in treatment (WHO, 2013). 
The World Health Organization forecasts that by 2030, heart failure will 
be a leading cause of death (Mathers CD, 2006; WHO, 2011). Various 
CVDs including cardiac hypertrophy (CH), hypertension and myocardial 
infarctions progress to heart failure if left untreated (de Couto et al., 
2010; Dupree, 2010). Pathological CH, induced by neurohormonal 
stimulation, hypertension or myocardial infarctions (MI), is character-
ized by the increase in size of cardiomyocytes and the remodeling of the 
extracellular matrix (ECM) (Kang and Izumo, 2003; Kehat and Mol-
kentin, 2010; Mlih et al., 2015; Watkins et al., 2011). The abnormal 
stimulation of various ECM proteases including cathepsins and matrix 
metalloproteinases (MMPs) have been proposed to contribute to the 
progression of cardiac remodeling (Abdulrahman et al., 2018; Cheng 
et al., 2012; Dhalla et al., 2009; Rodriguez et al., 2010; Wilson, 2001). 
The cysteine proteases, cathepsins, have been demonstrated to 
contribute to cardiac remodeling (Brömme and Wilson, 2011; Liu et al., 
2013; Müller and Dhalla, 2012; Wu et al., n.d.). Previous studies have 
demonstrated that stimulation of H9c2 cardiomyoblasts with Ang II, a 
hypertrophic stimulator (Wu et al., n.d.). Cat B protein expression and 
the inhibition of Cat B resulted in attenuation of cardiomyocyte hyper-
trophy (Wu et al., n.d.). Similarly, in vivo, the knockout of Cat B atten-
uated pressure overload-induced CH, fibrosis, and apoptosis (Wu et al., 
n.d.). Cat B mRNA and protein expression were demonstrated to be 
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increased in human dilated cardiomyopathy (Ge et al., 2006). Clearly, 
Cat B has a crucial function in hypertrophy. 
Acidification of the peri- and extracellular spaces in settings of 
altered cell proliferation has been shown to activate Cat B (Bourguignon 
et al., 2004; Greco et al., 2014; Rozhin et al., 1994). In various forms of 
carcinomas, this type of pericellular acidification is caused by the 
stimulation of the Na+/H+ exchanger isoform 1 (NHE1), a regulator of 
intracellular pH (Bourguignon et al., 2004; Malo and Fliegel, 2006). 
NHE1 is a ubiquitously expressed housekeeping glycoprotein, which 
exchanges one intracellular H+ for one extracellular Na+ and is the only 
cardiac specific plasma membrane isoform of the NHE family (Mohamed 
and Mraiche, 2015). Increased activation of NHE1 is a key factor for the 
development of various CVDs including CH (Fliegel, 2009; Liu et al., 
2013; Wu et al., n.d.; Xue et al., 2010). Inhibition of NHE1, both in vivo 
and in vitro, has been demonstrated to regress hypertrophy (Javadov 
et al., 2008, 2009; Marano et al., 2004; Mohamed and Mraiche, 2015). 
The cellular mechanism by which NHE1 inhibition suppresses the hy-
pertrophic response is not known. However, stimulation of NHE1 is 
known to promote Cat B activity in breast cancer cells (Bourguignon 
et al., 2004) suggesting that NHE1 and Cat B activities might be related. 
Whether the anti-hypertrophic effects of NHE1 inhibitors act down-
stream through Cat B in cardiomyocytes is not known. 
It has also been suggested that in a malignant cell line, an increase in 
the pericellular acidic pH results in the relocation of the lysosomes. The 
acidic pericellular pH also enhances the secretion of Cat B into the 
extracellular space (Rozhin et al., 1994). Furthermore, the release of Cat 
B into the ECM induces the activation of MMP-9 (Giusti et al., 2008). In 
the myocardium, MMP-9 contributes to ECM remodeling and failure 
(Singh et al., 2004; Stempien-Otero et al., 2006). Interestingly, MMP-9 
activity has also been demonstrated to be enhanced in CCL39 lung fi-
broblasts upon the activation of NHE1 with phenylephrine (Taves et al., 
2008). Recently, the interaction of Cat B and MMP-9 with NHE1 has 
been shown to promote ECM degradation in breast cancer (Greco et al., 
2014). These studies suggest a putative pathway by which NHE1 inhi-
bition reduces Cat B and in turn prevents MMP-9 activation and protects 
against hypertrophy. 
To verify the role of Cat B in the anti-hypertrophic effect of NHE1 
inhibition, we examined the effect of the NHE1-specific inhibitor N-[2- 
methyl-4,5-bis(methylsulphonyl)-benzoyl]-guanidine, hydrochloride 
(EMD, EMD87580; 10 μM) on the hypertrophic phenotype, Cat B protein 
and mRNA expression, Microtubule-associated protein light chain 3 
(LC3)-I/II protein expression and MMP-9 activity in Ang II-treated H9c2 
cardiomyoblasts. 
2. Materials and methods 
2.1. Materials 
All routine chemicals were obtained from BD Biosciences (San Jose, 
CA), Fisher Scientific (Ottawa, ON) or Sigma (St. Louis, MO). EMD 
87580 (EMD) was a generous gift from Dr. N. Beier of Merck KGaA 
(Frankfurt, Germany). Primary antibodies used for Western blotting 
including rabbit polyclonal Cat B (sc-13985) (Amantini et al., 2015) and 
rabbit polyclonal MMP-9 (sc-10737) (Li et al., 2014) were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal 
anti-NHE1 (ab67314) and α-tubulin (ab4074) antibodies were from 
Abcam (Cambridge, MA). Rabbit polyclonal anti-LC3 A/B (12741) was 
from Cell Signaling. Secondary antibodies were purchased from Abcam. 
2.2. Cell culture 
H9c2 myoblasts, a clonal cell line derived from the embryonic BD1X 
rat heart tissue (Hescheler et al., 1991) were obtained from European 
Collections of Cell Cultures (ECACC) and cultured in DMEM/F12 1:1 
culture media supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin at 37 ◦C in a humidified atmosphere (95% 
O2–5% CO2) (Hescheler et al., 1991; Riaz, 2016). Watkins et al., (2011) 
has recently demonstrated that the H9c2 cell line shows a similar hy-
pertrophic response to primary neonatal cardiomyocytes including 
membrane morphology, G-signaling protein expression and electro-
physiological properties (Watkins et al., 2011). In addition, Watkins 
et al. (2011) and others have demonstrated that the H9c2 cell line had 
hypertrophy-associated traits when stimulated with hypertrophic agents 
in vitro. Cardiomyoblasts were seeded at a density of 2 × 105 cells in 35 
mm culture dishes. The cells were starved in serum free maintenance 
media for 24 h, and treated with Ang II (10 μM), Ang II+EMD (EMD 
87580; NHE1 inhibitor), Ang II+CA-074 Methyl Ester (Me); Cat B in-
hibitor), EMD (10 μM), or CA-074Me (10 μM) alone for 24 h. Ang II and 
EMD were dissolved in distilled water and CA-074Me was dissolved in 
dimethyl sulfoxide (DMSO). 
2.3. Western blot analysis 
H9c2 cardiomyoblasts were lysed using radio-immunoprecipitation 
protein assay (RIPA) buffer as described earlier (Mraiche and Fliegel, 
2011) (Fliegel, 2009; Liu et al., 2013; Wu et al., n.d.; Xue et al., 2010). 
Briefly, cell lysates were centrifuged at 16,000 g for 15 min at 4 ◦C and 
the supernatant containing the proteins were collected (Riaz, 2016). 
Total amount of protein present was quantified using the DC protein 
assay kit (Biorad). 15–25 μg of protein was separated on 15% or 9% 
SDS-PAGE and transferred on to nitrocellulose membranes. The mem-
branes were probed with anti-Cat B antibody, which recognizes bands at 
37 kDa (pro-Cat B) and 25 kDa (active-Cat B) (Bien et al., 2004), rabbit 
polyclonal anti-MMP-9, rabbit polyclonal anti-NHE1, rabbit polyclonal 
anti-LC3 A/B. Anti-α-tubulin was used as a loading control. Immuno-
reactive proteins were visualized using enhanced chemiluminescence 
(Amersham Biosciences) and imaged using the Alpha Innotech Fluo-
rChem Imager (R&D Systems). The images of the Western blot bands 
were then quantified using Scion Image software (Scion Corporation) by 
densitometry analysis (Sotanaphun et al., 2009). 
2.4. Gelatin zymography 
Non reduced protein samples (80 μg) were loaded on to resolving 
gels prepared by including 0.2% final concentration gelatin to acryl-
amide polymerization mixture (Riaz, 2016). After SDS PAGE, the gels 
were washed with 2.5% Triton X-100 and then incubated for 24 h at 37 
◦C in substrate buffer (50 mM Tris HCl, 0.15 M NaCl, 5 mM CaCl2, and 
0.05% NaN3, pH 7.6). The gels were stained with 1% Coomassie blue 
R-250 in acetic acid:methanol:water (1:2.5:6.5) for 1 h and then 
destained with the same solvent. The gels were then imaged to observe 
gelatinolytic activity. 
2.5. Reverse transcription-polymerase chain reaction (RT-PCR) 
RNA was extracted from cultured cells using TRIzol reagent and 
the concentration of RNA was determined using spectrophotometer 
(Nanodrop, 2000c, Thermo Scientific). cDNA was synthesized by 
reverse transcribing 2 μg of total RNA using High capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) (Riaz, 2016). The 
cDNA product was amplified using thermal cycler (Mastercycler, 
Eppendorf). 50–175 ng from the cDNA product was used for each 
PCR reaction. The PCR steps included initial denaturation of sam-
ples for 3 min at 94 ◦C followed by 35 cycles of denaturation (94 
◦C for 45 s), annealing (60 ◦C for 30 s) and extension (72 ◦C for 1 
min). The reaction ended with a final extension (72 ◦C for 10 min). 
Cat B cDNA was amplified using 5′-GGGGGAAATCTACAAAAATG-3′
and antisense 5′-AAAGACTCCTATCTGCCTCACT-3′ and ANP cDNA 
was amplified using sense 5′-CTGCTAGACCACCTGGAGGA-3, anti-
sense 5′-AAGCTGTTGCAGCCTAGTCC-3. The control β-actin cDNA 
was primed with sense 5′-GTTCCGATGCCCGAGGCTCT-3′ and anti-
sense 5′-GCATTTGCGTGCACAGATGGA-3′. PCR products were then 
S. Riaz et al.                                                                                                                                                                                                                                     
European Journal of Pharmacology 888 (2020) 173420
3
electrophoresed on 2% agarose gels stained with ethidium bromide. 
Cat B and ANP mRNA bands were imaged using the Alpha Innotech 
FluorChem Imager. The changes in Cat B and ANP mRNA levels 
were normalized to β-actin and quantified using Scion Image 
software. 
2.6. Measurement of cell surface area of H9c2 cardiomyoblasts 
Briefly, cardiomyoblasts were seeded in 35 mm culture dishes at a 
density of 3 × 104 cells per dish (Riaz, 2016). After treatment period, the 
cells were rinsed with 1X Phosphate Buffer Saline (PBS), fixed with 4% 
formaldehyde and stained with 0.5% crystal violet in 2% ethanol. A 
minimum of 10 representative cells were considered from three dishes, 
the average of which represented as one n value. Cell surface area was 
calculated using AxioVision Imaging software (Carl Zeiss 
Microimaging). 
2.7. Measurement of protein content of H9c2 cardiomyoblasts 
Protein content was measured as described previously (Merten et al., 
2006). Briefly, control and treated cardiomyoblasts were harvested with 
trypsin (Riaz, 2016). The total number of cardiomyoblasts present per 
dish is counted with a hemocytometer. Protein concentration of car-
diomyoblasts lysed with RIPA buffer was determined with Biorad DC 
protein assay kit. Protein content was calculated by dividing total 
amount of protein (μg) by the total number of cardiomyoblasts. 
2.8. Localization of the lysosomes 
Briefly, following treatment, cardiomyoblasts were incubated with a 
cell permeable acidotropic probe, namely, LysoTracker Red DND-99 (75 
μM) (Invitrogen) for 30 min, which selectively binds to vacuoles with 
low internal pH (Riaz, 2016). The cells were then incubated with 1 μM 
HOECST for another 30 min. Finally, the cells were viewed under a 
fluorescence microscope (OlympusIX70; Olympus Corp). 
2.9. Statistical analysis 
Values were expressed as % control ± S.E.M. Student t-test and 
ANOVA followed by Bonferroni was used to calculate differences be-
tween groups where a P < 0.05 was considered significant. 
3. Results 
3.1. Ang II stimulates a concentration dependent increase in Cat B protein 
expression in H9c2 cardiomyoblasts 
H9c2 cardiomyoblasts were treated with 1, 10, or 100 μM, or 1, 10, 
or 100 nM Ang II for 24. Western blot analysis showed that stimulation 
with 10 μM Ang II significantly increased (P < 0.05) (Fig. 1A and B) the 
expression of pro-Cat B (37 kDa) and active-Cat B (25 kDa) protein (Bien 
et al., 2004). A concentration of 100 μM Ang II induced significant cell 
death which was confirmed by counting the number of cardiomyoblasts 
using a hemocytometer and comparing it to the non-treated set. This 
could likely be the reason for a decrease in Cat B protein expression at 
100 μM. 
3.2. Effect of EMD or CA-074Me on hypertrophy 
Previous reports have demonstrated that induction of cardiomyocyte 
hypertrophy due to various extracellular stimuli could be reduced by 
NHE1 inhibitors (Javadov et al., 2009; Marano et al., 2004; Mohamed 
and Mraiche, 2015). In our study, 10 μM of Ang II significantly enhanced 
the expression of ANP mRNA (P < 0.05) (Fig. 2A and B), total protein 
content (P < 0.05) (Fig. 2C) and cell surface area (P < 0.05) (Fig. 2D and 
E) in H9c2 cardiomyoblasts. These effects were significantly regressed in 
the presence of EMD or CA-074Me. 
3.3. Effect of EMD on Cat B protein and gene expression 
Protein and RNA samples extracted from EMD treated H9c2 car-
diomyoblasts were subjected to Western blotting and RT PCR, respec-
tively, to identify whether Cat B protein and mRNA expression are 
interrelated to the anti-hypertrophic property of EMD. Immunoblot and 
gene amplification analysis showed that Cat B protein and gene 
expression were significantly enhanced following treatment with 10 μM 
Ang II (P < 0.05), an effect that was significantly reduced in the presence 
of EMD (P < 0.05) (Fig. 3A–D). Similarly, Cat B protein and gene 
expression were significantly reduced when pre-treated with CA-074Me 
(P < 0.05) (Fig. 3A–D). 
3.4. Effect of EMD or CA-074Me on lysosomal integrity 
The acidic environment within the lysosomes facilitates the locali-
zation of Cat B and functions to degrade and eliminate unwanted pro-
teins (Cheng et al., 2012). In order to identify the effect of EMD or 
CA-074Me on the localization and morphology of lysosomes, H9c2 
cardiomyoblasts treated with 10 μM Ang II in the presence of EMD or 
CA-074Me were stained with acidotropic probe LysoTracker Red. 
Stimulation of cardiomyoblasts with Ang II revealed an increased dis-
tribution and dispersion of the lysosomes when compared to the 
non-treated (Fig. 4A). Treatment with EMD or CA-074Me prevented the 
distribution of the lysosomes induced by Ang II (Fig. 4A). 
3.5. Effect of EMD on Cat B protein expression in the extracellular 
environment 
Our findings suggest that treatment with EMD results in less 
dispersion and distribution of the lysosomes, which may be indicative of 
Fig. 1. Effects of Angiotensin II on cathepsin B (Cat B) protein expression. (A) 
Representative Western blot of Cat B protein expression in cell lysates of H9c2 
cardiomyoblasts treated with 1 μM, 10 μM, 100 μM, 1 nM, 10 nM or 100 nM 
Ang II for 24 h. Immunoblotting was against pro-Cat B (37 kDa) and active-CatB 
(25 kDa) and α-tubulin (50 kDa). (B) Bar graphs representing quantification of 
relative levels of Cat B protein expression (n = 7) normalized to α-tubulin. 
Results are expressed as a % control (non-treated (NT)) ± %S.E.M. *P < 0.05 vs. 
control. Ang II, angiotensin II; Cat B, cathepsin B; NT, non-treated. 
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less extrusion of Cat B into the extracellular media. Hence, we assessed 
the levels of Cat B in conditioned media of H9c2 cardiomyoblasts treated 
with Ang II in the presence or absence of EMD or CA-074Me. Western 
blot analysis showed that Ang II treatment significantly increased Cat B 
protein (P < 0.05) (Fig. 4B and C). The increase Cat B protein expression 
was significantly reduced in the presence of EMD (P < 0.05) (Fig. 4B and 
C). Similarly, pre-treatment with CA-074Me significantly reduced the 
Cat B protein expression in the media (P < 0.05) (Fig. 4B and C). 
3.6. Effect of EMD on MMP-9 gelatinolytic activity 
A recent study has shown that acidification of the extracellular space 
increases the secretion of MMP-9 and Cat B (Greco et al., 2014). It was 
also identified that Cat B is involved in the pH dependent activation of 
pro-MMP-9 (Giusti et al., 2008). Hence, we examined MMP-9 activity in 
the conditioned media of H9c2 cardiomyoblasts stimulated with Ang II 
in the presence or absence of EMD or CA-074Me treatment. Gelatin 
zymography showed that MMP-9 gelatinolytic activity was significantly 
increased following stimulation with 10 μM Ang II (P < 0.05) (Fig. 4D 
and E), an effect that was significantly reduced upon stimulation with 
EMD (P < 0.05) (Fig. 4D and E). Similarly, pre-treatment with 
CA-074Me significantly lowered MMP-9 activity (P < 0.05) (Fig. 4D and 
E). 
3.7. Effect of EMD on the autophagic response 
Stress activated autophagy-lysosomal pathway is regulated by Cat B 
(activated by acidic pH) and NHE1 (Sun et al., 2013). LC3 II/I protein 
expression is generally used to assess autophagy. The level of LC3-II and 
LC3-I proteins were measured by immunoblot analysis in H9c2 car-
diomyoblasts treated with 10 μM Ang II in the presence and absence of 
EMD or CA-074Me. Our results revealed that the ratio of LC3-II to LC3-I 
protein expression was significantly elevated following treatment with 
10 μM Ang II (P < 0.05) (Fig. 5A and B). This effect was significantly 
reduced upon treatment with EMD (P < 0.05) or CA-074Me (P < 0.05) 
(Fig. 5A and B). 
4. Discussion 
Activation and enhanced expression of NHE1 and proteases such as 
cathepsins have been proposed to contribute to CH (Cheng et al., 2012; 
Müller and Dhalla, 2012). NHE1 inhibitors have been shown to regress 
the hypertrophic response to various extracellular stimuli (Giusti et al., 
2008; Kostoulas et al., 1999). Interestingly, Cat B in a breast cancer 
model was shown to be activated in response to a fall in the extracellular 
pH mediated by over active NHE1 (Bourguignon et al., 2004). In addi-
tion, Cat B was demonstrated to directly interrelate with NHE1 and 
cause ECM degradation (Greco et al., 2014). Whether the 
anti-hypertrophic effect of NHE1 inhibition occurs due to the attenua-
tion of Cat B remains unclear. 
Fig. 2. Influence of inhibition of NHE1 or cathepsin B (Cat B) on the hypertrophic phenotype of H9c2 cardiomyoblasts. (A) Representative DNA agarose gel of ANP 
and β-actin mRNA expression in H9c2 cardiomyoblasts treated with Ang II in the presence or absence of EMD or CA-074Me for 24 h. (B) Bar graphs representing 
quantification of ANP mRNA expression in H9c2 cardiomyoblasts normalized to β-actin (n = 7). Results are expressed as a % of control (non-treated (NT)) ± %S.E.M. 
*P < 0.05 vs. control, #P < 0.05 vs. Ang II. (C) Protein content of H9c2 cardiomyoblasts treated with Ang II in the presence and absence of EMD or CA-074Me for 24 
h expressed as % of control (n = 4). (D) Representative crystal violet stained microscopy images of H9c2 cardiomyoblasts treated with Ang II in the presence and 
absence of EMD or CA-074Me for 24 h. (E) Cell surface area of at least 30–40 H9c2 cardiomyoblasts from 3 to 4 individual dishes (n = 4). Results are expressed as a % 
of control (non-treated (NT)) ± %S.E.M. *P < 0.05 vs. control, #P < 0.05 vs. Ang II. Ang II, angiotensin II; ANP, atrial natriuretic peptide; DNA, deoxyribonucleic 
acid; NT, non-treated. 
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4.1. Ang II induces the expression of Cat B in H9c2 cardiomyoblasts 
The role of Cat B in cardiac remodeling has been demonstrated in in 
vitro, in vivo and in human failing hearts. A previous in vitro study 
demonstrated that inhibition of Cat B reduced cardiac hypertrophy 
mediated through ASK1/JNK pathway (Wu et al., n.d.). In vivo, pressure 
overload induced cardiac remodeling process was attenuated in the 
absence of Cat B (Wu et al., n.d.). Moreover, the inhibition of Cat B with 
CA-074Me resulted in significant reduction of cardiomyocyte size, car-
diac fibrosis and attenuated cardiac dysfunction. (Liu et al., 2013). The 
expression of Cat B mRNA and protein were significantly higher in 
failing hearts compared with non-failing hearts (Ge et al., 2006). 
Our findings are in accordance with a previous study, which has 
demonstrated that Ang II induces Cat B expression/activity in the cur-
rent study, both the pro and active-Cat B protein were significantly 
elevated in H9c2 cardiomyoblasts when treated with 10 μM Ang II 
(Fig. 1A and B). Similarly, Wu et al. showed that Ang II increased Cat B 
protein expression in H9c2 cardiomyoblasts (Wu et al., n.d.). 
Other cathepsin isoforms have also been implicated in cardiac 
remodeling and hypertrophy (Müller and Dhalla, 2012). A previous 
study showed that gene and protein levels of Cat S, B, and L were 
increased in cultured neonatal rat cardiomyocytes (Cheng et al., 2006). 
Similarly, Cat S has been shown to be elevated in the myocardium of rats 
linked with hypertension induced heart failure (Cheng et al., 2006). Cat 
S were also enhanced in hearts obtained from humans with heart failure 
(Cheng et al., 2006). Phenylephrine-induced CH was more prominent in 
the absence of Cat L, in vitro (Sun et al., 2013). Another study reported 
that MI induced by left coronary artery ligation in wild-type rats caused 
rapid Cat L activation in the myocardium and its deficiency resulted in 
reduced cardiac function and survival post-MI (Sun et al., 2011). 
Moreover, Cat S deficiency enhanced cardiac fibrosis stimulated by Ang 
II (Pan et al., 2012). Although many forms of cathepsins have been 
proposed to contribute to CH, in our study we focused on Cat B, which is 
stimulated by an acidic pH (Bourguignon et al., 2004; Rozhin et al., 
1994), a major stimulus of NHE1 activity. Whether the various forms of 
cathepsins are simultaneously upregulated in a model of hypertrophy or 
the interplay between the various forms of cathepsins remains unknown. 
4.2. EMD reduces Cat B mediated hypertrophy 
In order to identify the role of Cat B in promoting hypertrophy, three 
hypertrophic markers namely, ANP mRNA, protein content and cell area 
were analyzed. Our results showed that 10 μM Ang II induced hyper-
trophy in H9c2 cardiomyoblasts (Fig. 2A–E). Inhibition of NHE1 or Cat B 
significantly decreased the hypertrophic effect (Fig. 2A–E). Pre- 
treatment with EMD significantly reduced Cat B protein and gene 
expression (Fig. 3A–D). Our results demonstrate for the first time that 
EMD reduced Cat B protein and mRNA expression in H9c2 cardiomyo-
blasts. Our findings reveal for the first time that the anti-hypertrophic 
effect of NHE1 inhibition may occur in part by reduced Cat B expres-
sion (Riaz, 2016). 
4.3. EMD or CA-074 reduces Cat B protein expression through MMP-9 
activity 
The acidic environment within the lysosomes facilitates localization 
of Cat B where it becomes functional to degrade and eliminate defective 
proteins (Cheng et al., 2012). A previous report has confirmed that 
relocation of lysosomes to cell edge and secretion of Cat B is associated 
with an acidic extracellular pH. Interestingly, this effect was inhibited 
with various broad and specific NHE inhibitors (Steffan et al., 2009). 
Hence, we focused to analyze the intracellular localization of lysosomes 
using the acidotropic probe LysoTracker Red in H9c2 cardiomyoblasts 
stimulated with Ang II in the presence and absence of EMD. Treatment 
with EMD or CA-074Me resulted in less distribution and dispersion of 
the lysosomes (Fig. 4A), which may be indicative of less secretion of Cat 
B into the extracellular media. The dispersion of the lysosomes can result 
in the release of the Cat B proteases into the cytosol or into the extra-
cellular compartment (Rozhin et al., 1994). Our study demonstrated for 
the first time that pro-Cat B protein levels were significantly increased in 
Fig. 3. Influence of inhibition of NHE1 by EMD on cathepsin B (Cat B) protein and gene expression. (A) Representative Western blot of Cat B protein expression in 
cell lysates of H9c2 cardiomyoblasts treated with Ang II in the presence or absence of EMD or CA- 074Me for 24 h. Immunoblotting was against pro-Cat B (37 kDa) 
and active-CatB (25 kDa) and α-tubulin (50 kDa). (B) Quantification of relative levels of Cat B protein expression (n = 6–7) normalized to α-tubulin. Results are 
expressed as a % of control (non-treated (NT)) ± %S.E.M. *P < 0.05 vs. control, #P < 0.05 vs. Ang II. (C) Representative agarose DNA gel of cathepsin B mRNA 
expression in H9c2 cardiomyoblasts treated with Ang II in the presence or absence of EMD or CA-074Me for 24 h cDNA amplification was against Cat B and β-actin. 
(D) Quantification of Cat B mRNA expression in H9c2 cardiomyoblasts normalized to β-actin (n = 7). Results are expressed as % of control (non-treated (NT)) ± %S.E. 
M. *P < 0.05 vs. control, #P < 0.05 vs. Ang II. Ang II, angiotensin II; Cat B, cathepsin B; DNA, deoxyribonucleic acid; NT, non-treated. 
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the extracellular compartment (Fig. 4B and C), an effect that was 
significantly reduced EMD or CA-074Me (Fig. 4B and C). It is to be noted 
that the pro-Cat B is enzymatically inactive, however studies have 
shown that pro-Cat B can also be induced by interactions with matrices, 
for example, human prostate carcinoma cells with collagen I gels or 
human bone explants (Mundel and Reiser, 2010). It has been demon-
strated that pro-Cat L could be activated by heparan sulphate (Ishidoh 
and Kominami, 1995). 
A previous study demonstrated that pro-Cat B retains some of its 
catalytic activity and as such, is capable of activating pro-MMP-9 (Giusti 
et al., 2008; Pungercar et al., 2009). Moreover, an in vivo study showed 
that CH does not occur in MMP-9 deficient mice after Ang II treatment, 
which suggests that MMP-9 has a crucial role in Ang II-induced cardiac 
hypertrophy (Weng et al., 2016). Therefore, we analyzed the MMP-9 
gelatinolytic activity in the conditioned media. Gelatin zymography 
revealed that MMP-9 gelatinolytic activity was significantly increased in 
conditioned media from H9c2 cardiomyoblasts treated with Ang II 
(Fig. 4D and E). However, this effect was significantly reduced upon the 
inhibition of NHE1 or Cat B (Fig. 4D and E). In our study, MMP-9 was 
detected only at 92 kDa in the gelatin zymograms, which is in agreement 
with previous studies (Giusti et al., 2008; Solli et al., 2013). The band 
corresponding to 92 kDa is mostly described as the inactive MMP-9. 
However, certain protein substrates have been shown to cause confor-
mational changes within the MMP-9 structure that result in the exposure 
of the active site without cleavage of the pro-peptides (Fedarko et al., 
2004; Freise et al., 2009). 
Fig. 4. Influence of inhibition of NHE1 or cathepsin B (Cat B) on lysosomal integrity. (A) Representative fluorescent images of the intracellular localization and 
morphology of lysosomes of H9c2 cardiomyoblasts treated with Ang II in the presence or absence of EMD or CA-074Me. H9c2 cardiomyoblasts were stained with the 
acidic probe, Lysotracker Red (n = 3). Influence of inhibition of NHE1 or cathepsin B on MMP-9 in the extracellular environment. (B) Representative Western 
blot of Cat B protein expression in the media of H9c2 cardiomyoblasts treated with Ang II in the presence or absence of EMD or CA-074Me for 24 h. Immunoblotting 
was against pro-Cat B (37 kDa). (C) Quantification of the relative levels of Cat B protein expression (n = 5). Results are expressed as a % of control (non-treated (NT)) 
± % S.E.M. *P < 0.05 vs. control, #P < 0.05 vs. Ang II. (D) Inhibition of NHE1 or Cat B reduces MMP-9 gelatinolytic activity. Representative zymogram of MMP-9 
gelatinolytic activity in conditioned media from H9c2 cardiomyoblasts treated with Ang II in the presence or absence of EMD or CA-074Me for 24 h. (E) Quanti-
fication of MMP-9 gelatinolytic activity in H9c2 cardiomyoblasts (n = 3). Results are expressed as a % of control (non-treated (NT)) ± %S.E.M. *P < 0.05 vs. control, 
#P < 0.05 vs. Ang II. Ang II, angiotensin II; Cat B, cathepsin B; MMP-9, matrix metalloproteinase-9. 
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4.4. EMD maintains the autosomal-lysosomal pathway 
Deregulation of various signaling pathways and cardiomyocyte 
autophagy lead to the development of pathological CH (Frey and Olson, 
2003; Heineke and Molkentin, 2006). Foregoing research also proved 
that regulation of pH by NHE1 is crucial in regulating autophagy in 
order to eliminate defective proteins (Togashi et al., 2013). Whether the 
anti-hypertrophic effects of NHE1 inhibitors reduce Cat B in association 
with cardiomyocyte autophagy remains unclear. 
LC3 is a ubiquitously found soluble protein in mammalian tissues 
and cultured cells (Tanida et al., 2008). During autophagy, autophago-
somes engulf cytoplasmic components, including cytosolic proteins and 
organelles. Alongside, a cytosolic form of LC3 (LC3-I) is conjugated to 
phosphatidylethanolamine to form LC3-II, which is transported to 
autophagosome membranes (Tanida et al., 2008). The final step of the 
autophagy–lysosomal pathway is the fusion of an autophagosome with a 
functioning lysosome. LC3-II stays on the membrane until it is degraded 
by the lysosome. Hence, the amount of LC3-II/LC3-I reflects autophagic 
activity, and detecting LC3 by immunoblotting has become a reliable 
and widely used marker for autophagic process (Levine and Kroemer, 
2008; Mizushima and Yoshimori, 2007). It is to be noted that an 
imbalance of protein homeostasis by dysfunction of the 
autophagy-lyosomal pathway may lead to pathological hypertrophy 
(Sandri, 2013; Zhao et al., 2007). 
Our results showed that the ratio of LC3-II/LC3-I protein expression 
was significantly increased (Fig. 5A and B). This effect was significantly 
reduced upon treatment with EMD or CA-074Me (Fig. 5A and B). Our 
results showed that EMD or CA-074Me in H9c2 cardiomyoblasts stim-
ulated with Ang II reduced the expression of the ratio of LC3-II/LC3-I, 
which is indicative of impaired autophagy. 
5. Conclusion 
The inhibition of NHE1 or Cat B reduced the hypertrophic response 
indicating an important role of NHE1 and Cat B in the hypertrophic 
pathway. Our study demonstrated for the first time that inhibition of 
NHE1 with EMD reduced Cat B protein and gene expression suggesting 
that the anti-hypertrophic effect of EMD, an NHE1 inhibitor, is mediated 
by Cat B. Furthermore, inhibition of NHE1 and Cat B resulted in less 
dispersion of the lysosomes and also reduced the protein expression of 
the LC3II to LC3-I ratio. This suggests that the autophagy-lysosomal 
pathway plays a role in mediating the anti-hypertrophic. Dispersion of 
the lysosomes resulted in the secretion of Cat B into the extracellular 
Fig. 5. Influence of inhibition of NHE1 or cathepsin B (Cat B) on autophagy. 
(A) Representative Western blot of LC3 protein expression of H9c2 car-
diomyoblasts treated with Ang II in the presence and absence of EMD or CA- 
074Me for 24 h. Immunoblotting was against LC3-I and II (14 and 16 kDa). 
(B) Quantification of relative levels of LC3-II to LC3-I protein expression (n =
5). Results are expressed as a % of control (non-treated (NT)) ± %S.E.M. *P <
0.05 vs. control, #P < 0.05 vs. Ang II. Ang II, angiotensin II; NT, non-treated. 
Fig. 6. Schematic Diagram Illustrating Pathway by Which Inhibition of NHE1-reduces cathepsin B induced cardiomyocyte-hypertrophy through the inhibition of 
MMP-9. The inhibition of NHE1 reduces cathepsin B protein and gene expression and MMP-9 activity, and cardiomyocyte hypertrophy. NHE1, Na+/H + Exchanger 
1; Cat B, cathepsin B; MMP-9, matrix metalloproteinase-9. Ang II, angiotensin II. 
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space where it activated pro-MMP-9. These effects were reduced upon 
inhibition of NHE1 or Cat B (Fig. 6) (Riaz, 2016). The extent to which the 
conclusions of the present work may be applicable to native car-
diomyoblasts and in vivo heart will require further studies using 
appropriate animal models. This shall confirm the results obtained in the 
present study. 
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